Respiratory system compliance at the same PEEP level is similar in COVID and non-COVID ARDS.

BACKGROUND: The comparison of respiratory system compliance (Crs) between COVID and non-COVID ARDS patients has been the object of debate, but few studies have evaluated it when considering applied positive end expiratory pressure (PEEP), which is one of the known determinants of Crs itself. The aim of this study was to compare Crs taking into account the applied PEEP.
METHODS: Two cohorts of patients were created: those with COVID-ARDS and those with non-COVID ARDS. In the whole sample the association between Crs and type of ARDS at different PEEP levels was adjusted for anthropometric and clinical variables. As secondary analyses, patients were matched for predicted functional residual capacity and the same association was assessed. Moreover, the association between Crs and type of ARDS was reassessed at predefined PEEP level of 0, 5, 10, and 15 cmH2O with a propensity score-weighted linear model.
RESULTS: 367 patients were included in the study, 276 patients with COVID-ARDS and 91 with non-COVID ARDS. The association between Crs and type of ARDS was not significant in both the complete cohorts (p = 0.17) and in the matched cohorts (p = 0.92). This was true also for the propensity score weighted association at PEEP 5, 10 and 15 cmH2O, while it was statistically significant at PEEP 0 (with a median difference of 3 ml/cmH2O, which in our opinion is not clinically significant).
CONCLUSIONS: The compliance of the respiratory system is similar between COVID ARDS and non-COVID ARDS when calculated at the same PEEP level and while taking into account patients' anthropometric characteristics.

Background

Acute respiratory distress syndrome (ARDS) is common in severe novel coronavirus 2019 disease (COVID-19) [1]. Recently, it was suggested [2] that respiratory system compliance (Crs) might be different in COVID-ARDS when compared to ARDS from other diseases, due to the existence of two different “phenotypes” in COVID ARDS which might not be present in non-COVID ARDS. These phenotypes have been identified as Type L, characterized by Low elastance (i.e., high compliance) and Type H, characterized by High elastance (i.e., low compliance) [2]. Subsequent studies have compared Crs between COVID ARDS and non-COVID ARDS, but the debate concerning differences in Crs between COVID and non-COVID ARDS patients is still ongoing, due to conflicting findings [3-6].

Crs is modified by Positive End Expiratory Pressure (PEEP) levels [7-11], but previous studies have compared Crs between COVID ARDS and non-COVID ARDS at different PEEP levels [3, 5, 12]. Only by knowing Crs at similar PEEP levels can the Crs of COVID and non-COVID ARDS patients be correctly compared, thus avoiding attributing to respiratory system characteristics what could be the effect of PEEP itself on Crs. Therefore, the aim of the study was to assess if Crs in COVID ARDS and non-COVID ARDS is similar or different when the applied PEEP is taken into account.

Methods

In this retrospective cohort study, data was collected from all consecutive adult subjects (over 18 years of age) with a diagnosis of ARDS (according to the Berlin Definition criteria [13]) to the Intensive Care Unit (ICU) of Poliambulanza Foundation Hospital of Brescia (Lombardy, Italy) from January 1st 2015 to May 1st 2021.The referral Ethics Committee (Comitato Etico di Brescia) approved the study (protocol number 4893).

Subjects were excluded from the analysis if: (a) they did not undergo invasive mechanical ventilation with sedation and paralysis; (b) no recordings of Crs at different PEEP levels during invasive ventilation with sedation and paralysis during the ARDS period were available.

Two cohorts of subjects were created: (1) subjects with COVID-19 ARDS, i.e., the ones with ARDS attributable to Severe Acute Respiratory Syndrome–CoronaVirus- 2 (SARS-CoV -2) infection. (2) subjects with non-COVID ARDS, i.e., ARDS subjects without SARS-CoV 2 infection. ARDS patients were included in this group if ICU admission occurred before February 18th 2020, the day of the first COVID-19 diagnosis in our region (RT-PCR test for SARS-CoV-2 was not performed before this date), or if they had a negative RT-PCR test for SARS-CoV-2 after 18th February 2021.

Data on respiratory mechanics were collected, on median, on the same day as ARDS diagnosis in both COVID ARDS and non-COVID ARDS (0 [0-1] and 0 [0-1] days after ARDS diagnosis, respectively, p = 0.51). Tracheal intubation was performed, on median, on the same day as ARDS diagnosis in patients with COVID ARDS and on the day before ARDS diagnosis in patients with non-COVID ARDS (0 [0-1] and 1 [0–1.5] days before ARDS diagnosis, respectively, p < 0.001).

All measurements were taken with patients in the semirecumbent position, sedated and paralyzed. Ventilatory settings were adjusted according to our ICU’s ventilation protocol [4]: Crs at different PEEP levels was assessed with a “PEEP trial”, setting volume controlled ventilation if not in use and maintaining the tidal volume set by the attending clinician in order to ensure a low-tidal volume ventilation. An end-inspiratory pause of 0.5 s was set and the respiratory rate was progressively decreased until complete exhalation was achieved. A stepwise increase (of 2 cmH2O) in PEEP level was performed, until an evident pattern of decrease of Crs with increasing PEEP was noticeable. The lowest PEEP level at which Crs was assessed in all patients was 4 cmH2O. A PEEP of 0 and 2 cmH2O could be applied in patients with SpO2 higher than 85%. Each PEEP level was maintained for at least 2 min [14]. When the PEEP trial was completed, the previous ventilatory mode and respiratory rate were restored, and PEEP was set to obtain a total PEEP equal to the PEEP associated with the highest Crs obtained during the PEEP trial. The PEEP trial was stopped when a systematic increase in driving pressure was seen with increasing PEEP, or when adverse cardiovascular effects or a decrease in SpO2 greater than 10% of baseline were noticed.

The “PEEP trial” was completed, on median, on the same day as intubation in all groups.

Data (demographic, clinical, laboratory data and outcome) were extracted from the electronic medical chart of enrolled subjects.

Measurements and calculations

Respiratory system compliance (Crs) was calculated as the ratio between tidal volume and driving pressure, which is the pressure distending the lungs, and is calculated as end inspiratory pressure (Plateau Pressure) minus PEEP [7].

“Best compliance” was identified as the highest Crs obtained at the tested PEEP levels and “best minimum PEEP” was the lowest PEEP with which the best compliance was obtained in each patient.

Body mass index (BMI) was calculated as kg/m2, where kg is the weight in kilograms and m2 is the square of the height in meters.

Ideal Functional Residual Capacity (FRC) was calculated as 2.34·height in meters + 0.01·age in years − 1.09 in male patients and as 2.24·height in meters + 0.001·age in years − 1.00 in female patients [15]. Predicted FRC was obtained correcting for BMI with the following formula 231.9·e(−0.070·BMI) + 55.2 [16].

Ventilatory ratio was calculated as (tidal volume·respiratory rate·PaCO2)/(ideal body weight·100 ml/min·37.5 mmHg), where tidal volume is expressed in milliliters and 37.5 is assumed to be the PaCO2 during the ideal minute ventilation [17].

Ideal body weight (IBW) was calculated as 50 + (0.91·[height in centimeters − 152.4]) for men, and as 45.5 + (0.91·[height in centimeters − 152.4]) for women.

Study outcomes

The main study outcome was to assess if the Crs of the respiratory system was independently associated with the type of ARDS (COVID ARDS or non-COVID ARDS) when weighted for PEEP level and patients’ baseline characteristics.

Statistical analysis

Sample size analysis was conducted with Montecarlo simulation based on data collected for a previous study [4]. Two hundred and sixty patients, hypothesising a ratio between COVID and non-COVID ARDS of 0.30, would guarantee a power of 0.80 to identify a difference in Crs between the two groups of 5 ml/cmH2O, with a type I error frequency of 0.05.

Data are shown as count (percentage) or median (interquartile range) and comparison between non-COVID ARDS and COVID ARDS were performed with χ2 test and Wilcoxon rank-sum test, respectively.

We planned to analyze the association between Crs and type of ARDS at different PEEP levels, using linear mixed models. The dependent variable was Crs and the following covariates were chosen a priori: type of ARDS (COVID vs non-COVID), PEEP, age, sex, BMI, Ventilatory Ratio, tidal volume, PaO2/FIO2, with patients as random effect.

Two secondary analyses were planned, with the aim to repeat the analysis on matched samples: (1) two cohorts of non-COVID and COVID ARDS were created, matched for predicted FRC. Matching was performed with the nearest neighbor method. The association between Crs and the type of ARDS (COVID versus non-COVID) was assessed with linear mixed models with interaction, using the type of ARDS and PEEP level at which Crs was measured as covariate, and patients as random effect. (2) The average respiratory system compliance (Crs,avg) was calculated in each patient at a PEEP level of 0, 5, 10, and 15 cmH2O, taking the average Crs obtained at a PEEP of 0, 5, 10 and 15 cmH2O ± 2 cmH2O. The association between Crs,avg and type of ARDS (COVID versus non-COVID) was reassessed at each of the four PEEP levels with linear model weighted with stabilized Inverse Probability Treatment Weighting obtained by propensity score [18]. Propensity score was calculated using age, sex, BMI, Ventilatory Ratio, tidal volume (used in the PEEP trial) and PaO2/FIO2 as covariates.

The analyses were repeated excluding non-COVID patients with extrapulmonary ARDS.

Missing values were imputed with Multivariate Imputation by Chained Equations (Predictive Mean Matching). A p value lower than 0.05 was considered significant. Statistical analyses were performed with R 3.6.3 (R Core Team, 2021. R Foundation for Statistical Computing, Vienna) [19].

Results

Three hundred sixty seven subjects were included in the study, 276 with COVID-ARDS and 91 with non-COVID ARDS (Fig. 1). Patient characteristics are shown in Table 1. In 24% of non-COVID ARDS patients, the cause of ARDS was extrapulmonary. Mean arterial pressure, central venous pressure, number of patients on norepinephrine and norepinephrine dose (mcg·kg−1·min−1) and daily urine output did not differ between COVID and non-COVID ARDS patients. Heart rate and lactate had a statistically significant difference, which we believe is clinically insignificant (median heart rate 92 beats·minute [IQR 78, 105] and 83 [IQR 69, 97] in non-COVID and COVID ARDS, respectively, p = 0.001; median lactate 1.1 [IQR 0.9, 1.7] mmol·l−1 and 0.9 [ IQR 0.8, 1.2] mmol·l−1 in non-COVID and COVID ARDS, respectively, p = 0.001).

Fig. 1

Flowchart of patients included in the study. PEEP positive end expiratory pressure, ARDS acute respiratory distress syndrome

Table 1

Patient characteristics

	Non-COVID ARDS	COVID ARDS	p value	COVID ARDS, matched cohort	p value*
Number of patients	91	276		91
Age, years	69 [59, 77]	68 [60, 73]	0.30	67 [63, 73]	0.40
Male sex	61 (67)	207 (75)	0.18	71 (78)	0.14
Respiratory rate, breaths·minute−1	21 [18, 25]	22 [20, 25]	0.16	22 [20, 24]	0.47
PEEP, cmH2O	8 [6, 10]	10 [8, 14]	< 0.001	10 [8, 12]	< 0.001
pH	7.34 [7.26, 7.43]	7.32 [7.23, 7.39]	0.02	7.34 [7.23, 7.39]	0.13
PaCO2, mmHg	44 [36, 53]	51 [44, 62]	< 0.001	49 [44, 60]	< 0.001
BMI, kg/m2	26 [22, 29]	28 [26, 32]	< 0.001	27 [25, 31]	0.005
VT, ml·kg IBW	6.4 [5.8, 7.1]	6.0 [5.4, 6.5]	< 0.001	5.9 [5.4, 6.3]	< 0.001
PaO2/FiO2	117 [89, 172]	103 [77, 138]	0.017	108 [80, 144]	0.12
Predicted FRC, liters	3.1 [2.7, 3.6]	3.1 [2.6, 3.4]	0.07	3.10 [2.7, 3.6]	0.71
Ventilatory Ratio	1.7 [1.3, 1.9]	1.9 [1.5, 2.2]	0.001	1.8 [1.5, 2.1]	0.027
Best Crs, ml/cmH2O	38 [29, 50]	40 [30, 48]	0.98	40 [30, 49]	0.82
Best minimum PEEP, cmH2O	6 [4, 8]	6 [2, 10]	0.64	4 [2, 8]	0.012

Data are shown as median [interquartile range], or count (percentage)

The last column (*) shows the comparison between non-COVID ARDS and COVID ARDS patients matched for predicted FRC. Best compliance is the highest Crs obtained at the tested PEEP levels

Best minimum PEEP is the lowest PEEP level associated with the highest Crs

PEEP positive end expiratory pressure, BMI body mass index, V tidal volume, IBW ideal body weight, FRC functional residual capacity, C respiratory system compliance, ARDS acute respiratory distress syndrome

Figure 2 shows Crs at different PEEP levels in non-COVID ARDS and COVID ARDS, in all enrolled patients and in the subset of patients which were matched for predicted FRC. The association between Crs and type of ARDS was not significant in both the complete cohorts (p = 0.17, see Additional file 1: Table S1) nor in the matched cohorts (p = 0.93, see Additional file 1: Table S2).

Fig. 2

Crs at different PEEP levels. Linear regression showing Crs at different PEEP levels in non-COVID ARDS and COVID ARDS, in all enrolled patients and in the subset of patients which were matched for predicted FRC. 0 = non-COVID ARDS patients, 1 = COVID ARDS patients. C respiratory system compliance, PEEP positive end expiratory pressure, ARDS acute respiratory distress syndrome, FRC functional residual capacity

Table 2 shows the results of the propensity score weighted association between Crs,avg and COVID status at different PEEP levels. Crs,avg was not associated with the ARDS type at PEEP 5, 10 and 15 cmH2O, showing a significant association at PEEP 0, despite a clinically insignificant difference. Estimates for the other variables are displayed in Additional file 1: Table S3.

Table 2

Results of the propensity score weighted association between Crs,avg and COVID status at different PEEP levels

	Non-COVID ARDS	COVID ARDS	p value
Number of patients	91	276
Crs,avg at PEEP 0 cmH2O	36 [26, 47]	33 [25, 42]	0.002
Crs,avg at PEEP 5 cmH2O	38 [30, 48]	37 [28, 44]	0.10
Crs,avg at PEEP 10 cmH2O	35 [28, 47]	36 [29, 44]	0.27
Crs,avg at PEEP 15 cmH2O	32 [22, 41]	32 [24, 40]	0.13

Data are shown as median [interquartile range]

C average respiratory system compliance, PEEP positive end expiratory pressure, ARDS acute respiratory distress syndrome

Figure 3 shows the distribution of Crs,avg at different PEEP levels.

Fig. 3

Distribution of Crs at different PEEP levels. 0 = non-COVID ARDS patients, 1 = COVID ARDS patients. C respiratory system compliance, PEEP positive end expiratory pressure, ARDS acute respiratory distress syndrome, FRC functional residual capacity

Results of the analyses excluding non-COVID patients with extrapulmonary ARDS are shown in Additional file 1: Tables S4–S7).

Updating the power analysis with collected data, we reached a power of 0.85 in detecting a change in compliance of 4 ml/cmH2O between COVID and non-COVID ARDS, with a type I error frequency of 0.05.

Discussion

This study shows that Crs is similar between COVID ARDS and non-COVID ARDS when weighted for PEEP level and patients’ baseline characteristics.

Previous studies comparing compliance between COVID-ARDS and non-COVID ARDS have shown conflicting results [3, 5, 12, 20], and the debate is still ongoing.

In particular, Haudebourg et al. [3] found similar Crs between the COVID and non-COVID ARDS patients, with values close to the ones found in our study (44 ml/cmH2O in COVID e 42 ml/cmH2O in non-COVID patients in their study, versus 40 ml/cmH2O in COVID e 38 ml/cmH2O in non-COVID in our study). However, the authors did not adjust for patient characteristics, the cohorts were small (30 with COVID-ARDS versus 30 with non-COVID ARDS) and patients were not matched. In another work comparing COVID and non-COVID ARDS patients [20], the two cohorts were matched on PaO2/FiO2, FiO2, PEEP and tidal volume, but there was no adjustment for patient characteristics. Higher (7 ml/cmH2O) average values of Crs were found in COVID-19 patients, but the sample size was small (30 patients) and set and total PEEP were different between COVID and non-COVID patients for both high and low PEEP levels. Other authors [5] found a higher median Crs in patients with COVID-19 (41 ml/cmH2O) than in those with classical ARDS (32 ml/cmH2O). The analysis was adjusted for sequential organ failure assessment score at ICU admission, sex, age, and PaO2/FiO2 ratio, but PEEP selection was not protocolized in their patients. Ferrando et al. [12] found a tendency towards the statistical significance (p 0.06) by comparing the Crs of non-COVID ARDS patients from different studies and the authors’ own data on COVID ARDS patients.

Apart from the intrinsic mechanical properties of the respiratory system, Crs is affected by applied PEEP [7-11]. COVID and non-COVID patients often receive different PEEP levels during mechanical ventilation [4, 20] therefore the comparison of Crs at different PEEP levels could reflect not only the impact of the disease on lung parenchyma but also the effects of the ventilatory treatment. Finding a similar Crs with a different applied PEEP in COVID and non-COVID ARDS [4] does not therefore exclude that the elastic properties of the respiratory system would have been different if the same level of positive pressure had been applied. On the other hand, a different Crs in COVID and non-COVID ARDS measured at a different PEEP levels cannot exclude similar mechanical properties of the respiratory system if the conditions of measurement had been the same [20].

Moreover, Crs depends on the FRC: the physiological variable which links compliance to FRC is called specific compliance (the ratio between Crs and FRC) [21-23]. Crs is dramatically different in healthy subjects with different FRCs, ranging on average between 5 and 7 ml/cmH2O in newborns [20] and 120 ml/cmH2O in adults [21]. When Crs is normalized by FRC, specific elastance (i.e., the ratio betweenFRC and Crs) has similar values in healthy newborns, children and adults [24]. In other words, despite similar elastic properties for each milliliter of lung tissue, the same amount of applied pressure gives a different increase in volume (and therefore of Crs) if the FRC is different. Matching for predicted FRC is meaningful when Crs is compared in COVID and non-COVID ARDS because FRC depends on height, age, sex and BMI [15, 16, 25], and some of these characteristics have been shown to be different in COVID and non-COVID ARDS (mainly sex and BMI) [5].

The effect of a different predicted FRC could explain the findings of Li Bassi et al. [26] who found, in their analysis on COVID-19 ARDS patients, a lower Crs in female patients: on average, females have a smaller stature than males, and this predicts lower FRC. Moreover, female sex by itself gives a lower predicted FRC than male sex for the same height and age, whereas BMI, which was higher for female patients in Li Bassi’s cohort, has an inverse relationship with predicted FRC. Therefore a lower Crs in female patients could be better explained by different anthropometric characteristics than by a different severity of the lung disease.

Based on these pathophysiological premises and clinical data, we designed an analysis which accounted for the effect of both PEEP and FRC.

Our analyses showed that Crs is not different between COVID and non-COVID ARDS if assessed at a similar PEEP level when the association was weighted for covariates, when it was carried out in a cohort matched for predicted FRC and when the inverse probability of treatment weighting was used to obtain unbiased estimates of average treatment effects. These results contribute to clarify the debate on the effect of the COVID-19 on alveolar damage, demonstrating that the inflammatory response involving the pulmonary parenchyma in ARDS affects the mechanical properties of the lung regardless of the primary disease. This is consistent with the pattern and definition of ARDS, which is considered as the common final pathway of different pulmonary and extrapulmonary diseases that spread their mediators of inflammation in the lungs [13, 27].

The similar pattern of Crs in COVID and non-COVID ARDS is supported by a similar best Crs obtained during the PEEP trial (median 38 versus 40 ml/cmH2O in non-COVID and COVID ARDS, respectively; see Table 1 for further details), and by a similar lowest PEEP at which the best Crs was obtained.

As shown in Fig. 3 it is apparent that, for some patients, a high PEEP level worsens respiratory system compliance, while improving it for some patients. We can therefore speculate that the appearance of two “phenotypes” is in fact the effect of a high PEEP level, and not of COVID ARDS itself, but further studies are needed to prove these findings.

Primary analysis was also weighted on dead space, as estimated by Ventilatory Ratio [17], since one of the main differences between COVID and non-COVID ARDS appears to be the dead space ventilation, expression of altered perfusion and vascular endothelial injury [4, 5, 28]. The peculiar increase in dead space ventilation of COVID-19 has been explained as a consequence of pulmonary microvascular thrombosis which locally increases the ventilation/perfusion ratio [5, 28, 29].

The dead space increase in COVID ARDS compared with non-COVID ARDS is confirmed in our analysis, with a higher ventilatory ratio in COVID ARDS compared to non-COVID ARDS in both unmatched and matched cohorts.

This study has two main limitations. First, it is a single center study and therefore requires further confirmation. Nonetheless, since we analyzed the association of Crs and type of ARDS for a wide range of PEEPs, we believe that our data could be generalized to centers which use a different approach to mechanical ventilation. Second, it is a retrospective study, even if data was prospectively collected. More research is needed on the subject in order to corroborate these findings.

Conclusion

The compliance of the respiratory system is similar between COVID ARDS and non-COVID ARDS when calculated at the same PEEP level and while taking into account patients’ anthropometric characteristics.

Additional file 1. Supplementary Material.